DTC Share Price Performance

DTC Community Fair Values

View all narratives

Recent DTC News & Updates

No updates

Defence Therapeutics Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

n/a

Earnings per share (EPS): -0.068
Gross Margin: 0%
Net Profit Margin: 0%
Debt/Equity Ratio: -626.8%

View full report ›

Defence Therapeutics Inc. Competitors

About DTC

Founded: 2017
Employees: n/a
CEO: Sebastien Plouffe
WebsiteView website: defencetherapeutics.com

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. It also offers Accuvac for dendritic cell cancer vaccines; a protein-based vaccine formulation against COVID and infectious diseases; and cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Canadian Market Performance

0.6%

19.7%

19.3%

8.5%

In the last week, the market has stayed flat, however the Communication Services sector stood out, gaining 4.6%. As for the longer term, the market has risen 19% in the past 12 months. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›

Defence Therapeutics Stock Price

DTC Share Price Performance

DTC Community Fair Values

Recent DTC News & Updates

Defence Therapeutics Inc. Key Details

Defence Therapeutics Inc. Competitors

Ronin Ventures

MDK Acquisition

Voice Mobility International

KP3993 Resources

Amilot Capital

SP Strategic Acquisition

Vanity Capital

Zoglo's Food

🎢 From Panic to Peak: Q2’s Wild Ride and What’s Next

🏛️ The Winners and Losers From The Stablecoin GENIUS Act